Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
Historical dosing, EPS management and stability statements require current product- and indication-specific review. Label narrative and GlobalRPh below-10 table are distinct recommendations.
Usual dosing and administration
Diabetic gastroparesis: oral treatment may be initiated for early manifestations; severe symptoms may require IM/IV treatment initially. A 10 mg IV dose is administered slowly over 1-2 minutes. Injection treatment for up to 10 days may be needed before oral conversion.
Emetogenic chemotherapy: dilute doses over 10 mg in 50 mL. Infuse over at least 15 minutes, beginning 30 minutes before chemotherapy; repeat every 2 hours for two doses, then every 3 hours for three doses. The initial two doses are 2 mg/kg with highly emetogenic agents such as cisplatin or dacarbazine; 1 mg/kg per dose may suffice with less-emetogenic regimens. The source describes 50 mg IM diphenhydramine for extrapyramidal symptoms.
Postoperative nausea/vomiting prevention: 10 mg IM near the end of surgery; 20 mg may be used.
Small-bowel intubation after failure to pass the pylorus with conventional maneuvers for 10 minutes: a single undiluted IV dose over 1-2 minutes. Adults and children over 14 years: 10 mg base; age 6-14: 2.5-5 mg; under 6: 0.1 mg/kg. The same single doses are described for radiologic examinations impaired by delayed gastric emptying.
Original preparation and stability comments
Normal saline is the preferred diluent. The source permits freezing a saline admixture for up to 4 weeks but reports degradation when frozen in D5W. Dilutions in saline, D5W, D5/0.45% saline, Ringer's or lactated Ringer's may be stored for 48 hours without freezing when protected from light, or 24 hours under ordinary lighting without protection. These are historical product-specific stability statements, not a newly assigned sterile-compounding beyond-use date.
Renal Dosing
The source label discussion recommends initiating approximately half the usual dose below CrCl 40 mL/min and adjusting to clinical response/safety. Its GlobalRPh table lists: above 40, no change; 10-40, 50% of normal; below 10, 25% of normal.
Hemodialysis
Use the below-10 regimen. Only 0-5% is dialyzable in the source; no supplemental dose is necessary.